Orchestra BioMed Holdings Inc. (OBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Orchestra BioMed Holdings Inc. stock (OBIO) is currently trading at $4.66. Orchestra BioMed Holdings Inc. PS ratio (Price-to-Sales) is 8.32. Analyst consensus price target for OBIO is $12.57. WallStSmart rates OBIO as Sell.
- OBIO PE ratio analysis and historical PE chart
- OBIO PS ratio (Price-to-Sales) history and trend
- OBIO intrinsic value — DCF, Graham Number, EPV models
- OBIO stock price prediction 2025 2026 2027 2028 2029 2030
- OBIO fair value vs current price
- OBIO insider transactions and insider buying
- Is OBIO undervalued or overvalued?
- Orchestra BioMed Holdings Inc. financial analysis — revenue, earnings, cash flow
- OBIO Piotroski F-Score and Altman Z-Score
- OBIO analyst price target and Smart Rating
Orchestra BioMed Holdings Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Orchestra BioMed Holdings Inc. (OBIO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Orchestra BioMed Holdings Inc. (OBIO) Key Strengths (2)
Revenue surging 12120.00% year-over-year
Strong operational efficiency: $22 kept per $100 revenue
Supporting Valuation Data
Orchestra BioMed Holdings Inc. (OBIO) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 8.3x annual revenue
Very expensive at 5.0x book value
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 37.78%
Supporting Valuation Data
Orchestra BioMed Holdings Inc. (OBIO) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Operating Margin. Profitability is solid with Operating Margin at 21.80%. Growth metrics are encouraging with Revenue Growth at 12120.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (8.32), Price/Book (5.05) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -109.40%, Profit Margin at -157.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -109.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 12120.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OBIO's Price-to-Sales ratio of 8.32x trades at a deep discount to its historical average of 53.91x (29th percentile). The current valuation is 91% below its historical high of 92.17x set in Mar 2026, and 18% above its historical low of 7.08x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~87.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Orchestra BioMed Holdings Inc. (OBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Orchestra BioMed Holdings Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 33M with 12120% growth year-over-year. The company is currently unprofitable, posting a -157.4% profit margin.
Key Findings
Revenue growing at 12120% YoY, reaching 33M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.04 indicates a conservative balance sheet with 42M in cash.
The company is unprofitable with a -157.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Orchestra BioMed Holdings Inc. maintain 12120%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Orchestra BioMed Holdings Inc..
Bottom Line
Orchestra BioMed Holdings Inc. is a high-conviction growth story with revenue accelerating at 12120% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -157.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:52 AM
About Orchestra BioMed Holdings Inc.(OBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.